GSK And Novartis Hit With $3m Fine In Australia For Misleading Voltaren Claims
Executive Summary
Marketing Voltaren Osteo Gel as more effective for treating osteoarthritis than the identically formulated Voltaren Emugel has landed GSK and Novartis with a substantial fine for breaching Australian Consumer Law.
You may also be interested in...
GSK Admits Voltaren Marketing Misled Australian Consumers, Now Facing Financial Penalty
GSK has admitted misleading Australian consumers with the marketing of its Voltaren range by claiming Osteo Gel was specifically formulated for treating osteoarthritis conditions, and was more effective than Emulgel to treat those conditions, when the two products were identically formulated. While a change to Osteo Gel's packaging has since satisfied Australia's Federal Court, GSK is still facing a financial penalty for its earlier conduct.
Euro Q1 Consumer Health Earnings Preview: Reckitt, Sanofi, Haleon, Bayer
Major Europe-based consumer health players Reckitt, Sanofi, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2024 results over the coming weeks.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.